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ABSTRACT 
 
Prescription drug abuse has been the fastest growing drug problem in the United 
States in recent years, and is the second most commonly abused category of illegal and 
illicit drugs, after marijuana (SAMHSA, 2013; Carnevale, 2011).  Reducing the 
morbidity and mortality associated with prescription drug abuse in challenging because 
multiple factors contribute to the problem.  Prescribing behaviors and the lack of 
education among providers and pharmacists along with inadequate counseling and 
monitoring of patients prescribed pain medication are important factors (Machikanti, 
2007; Okie, 2010).  Patients’ misuse or abuse, diversion or the sharing or sell of pills, and 
doctor shopping are also contribute to the problem (Okie, 2010).   Where they exist, 
prescription drug monitoring programs are underfunded and ineffective, and there are no 
established national prescription monitoring programs (Manchikanti, 2007) or substance 
abuse treatment guidelines for prescription pain relievers.  Additionally, nonmedical use, 
including diversion, is deviant behavior driven by a range of physical, mental and social 
health problems. Gilson and Kreis suggest that the problem can be effectively mitigated 
by the development of novel opioid formulations that reduce non medical use, 
improvements in prescription drug monitoring programs and a better, more accurate 
understanding of the problem (Gilson and Kreis, 2009).  Implementing strategies that 
target populations at greatest risk requires collaboration among local, state, federal, tribal 
health entities along with community partners.  Further defining populations at greatest 
risk is critical for development and implementation of effective interventions (JAMA, 
2012). 
This study aims to contribute to the understanding of the problem by describing 
the characteristics of persons who experienced an unintentional drug poisoning admission 
iv 
 
Clark County, Nevada between 2009 and 2013.    This research will help to better define 
the population that might benefit from targeted risk reduction education and monitoring 
to prevent continued drug seeking and use behaviors that may lead to continued 
morbidity and eventual mortality.  
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1CHAPTER 1
INTRODUCTION and PURPOSE
Drug overdose deaths have become the leading cause of injury death in the
United States (CDC, 2014). This is, in large part, thought to be a consequence of more
aggressive treatment of acute and chronic pain during the 1990s and the concurrent
emergence and explosion of prescription drug abuse over the past two decades. In 2007,
the U.S. witnessed approximately 27,000 unintentional drug overdose deaths, equating
to one every 19 minutes (CDC, 2012). In 2012, approximately nine of every ten
poisonings were caused by drugs and, of these, opioid analgesic pain relievers were
involved in more fatal poisonings than any other drug, including cocaine and heroin
(CDC-NCHS, 2012). According to the Centers for Disease Control and Prevention
(CDC), forty-six people die every day from prescription painkillers (CDC, 2011). The
trend in mortality mirrors both the increase in the medical use of pain analgesics and the
trend in substance abuse among Americans. Hydrocodone is the most frequently
prescribed drug in the U.S.; 120 million prescriptions were issued from 2005-2006
(Manchikanti and Singh, 2008).
Prescription drug abuse has been the fastest growing drug problem in the United
States in recent years, and is the second most commonly abused category of illegal and
illicit drugs, after marijuana (SAHMSA, 2013; Carnevale, 2011). Between 1992 and
2003, a period that witnessed a 14% population increase, the number of people abusing
controlled prescription drugs rose 81%, significantly more than the increase in the
number of people abusing marijuana (2 times more), cocaine (5 times more) and heroin
(60 times more) (Manchikanti, 2007). By 2008, although Americans only comprised
24.6% of the world population, the nation was consuming 80% of the global opioid
supply, 99% of the world’s hydrocodone, and two-thirds of illegal drugs globally
(Manchikanti and Singh, 2008). Many studies have demonstrated that both the use of
prescription drugs such as opioid analgesics and benzodiazepines, and overdoses
involving them have increased dramatically in the United States since the 1990s. CDC
reports that 113 people die and nearly 7,000 are treated in emergency rooms each day as
a result of drug overdose of which approximately 9 of 10 are attributed to prescription
drugs (CDC, 2014).
The epidemic of prescription drug abuse has great health, social and economic
costs. In addition to the concern for increased mortality related to prescription drug
abuse, people who abuse these drugs are at increased risk of unintentional injury, crime-
related injury and suicide (CDC, 2011).
Reducing the morbidity and mortality associated with prescription drug abuse in
challenging because multiple factors contribute to the problem. Prescribing behaviors
and the lack of education among providers and pharmacists along with inadequate
counseling and monitoring of patients prescribed pain medication are important factors
(Machikanti, 2007; Okie, 2010). Patients’ misuse or abuse, diversion or the sharing or
sell of pills, and doctor shopping are also contribute to the problem (Okie, 2010).
Where they exist, prescription drug monitoring programs are underfunded and
ineffective, and there are no established national prescription monitoring programs
(Manchikanti, 2007) or substance abuse treatment guidelines for prescription pain
relievers. Additionally, nonmedical use, including diversion, is deviant behavior driven
by a range of physical, mental and social health problems. Gilson and Kreis suggest that
3the problem can be effectively mitigated by the development of novel opioid
formulations that reduce non medical use, improvements in prescription drug monitoring
programs and a better, more accurate understanding of the problem (Gilson and Kreis,
2009). Implementing strategies that target populations at greatest risk requires
collaboration among local, state, federal, tribal health entities along with community
partners. Further defining populations at greatest risk is critical for development and
implementation of effective interventions (JAMA, 2012).
This study aims to contribute to the understanding of the problem by describing
the characteristics of persons who experienced an unintentional drug poisoning
admission Clark County, Nevada between 2009 and 2013. This research will help to
better define the population that might benefit from targeted risk reduction education
and monitoring to prevent continued drug seeking and use behaviors that may lead to
continued morbidity and eventual mortality.
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BACKGROUND AND SIGNIFICANCE
Drugs of Concern
Pharmaceutical drug abuse is primarily associated with opioid pain analgesics,
sedatives and depressants. Accounting for 74% (16,917) of the 22,810 prescription drug
related (DR) deaths in the U.S. in 2011 (CDC web), opioid pain analgesics are the
predominant drugs of concern. Medications in this class include hydrocodone (ie.
Vicodin), oxycodone (ie. Oxycontin, Percoset), morphine (eg. Kadian) and codeine
(NIH, 2011). The Drug Enforcement Administration (DEA) categorizes drugs based on
the drug’s accepted medical use and its potential for abuse and dependency (DEA
website). Categories range from Schedule I, drugs with no medical use to Schedule V
drugs, drugs with limited quantities of certain narcotics and low potential for abuse.
Non-combination opiates – morphine, codeine, hydromorphone and oxycodone - fall
into the DEA’s Schedule II category, drugs categorized by high abuse potential and
severe dependence liability.
When taken as prescribed, the Schedule II pain medications are effective in
reducing the perception of pain; however, because the drugs can produce other
symptoms such as drowsiness, mental confusion and, in some, a euphoric response, the
drugs are often used for non-medical reasons. People who abuse OxyContin may snort
or inject it. The illicit use of these drugs is increasing at epidemic proportions
(Manchikanti, Whitfield and Pallone, 2005). Nonmedical use increases risk for serious
medical complications, including overdose (NIH website, 2011).
5In addition to the opioid pain relievers, benzodiazepines, commonly known as
sedatives, are contributory and often used concomitantly with opioid pain medications.
According to CDC, benzodiazepines are frequently found among people treated in EDs
for misusing or abusing drugs and they are often detected in combination with opioids in
people who died of drug overdose (CDC, 2012).
Medical Use
Prescription drugs such as narcotic analgesics, anxiolytics, antidepressants,
stimulants and sedative-hypnotics play an important role in the management of chronic
pain and other conditions. Historically, long-term opioid pain therapy was avoided for
two reasons: 1) the fear that chronic use would lead to a high risk of addiction and 2)
the belief that opioids are not effective in the treatment of chronic, neuropathic pain
(Ballantyne, 2012). Throughout the 1980s and 90s, concern around the under treatment
of pain and the collective belief in both the efficacy of use in the treatment of acute and
cancer pain allowed for the consideration of treatment of other forms of pain that were
thought to be risky because of the fears of addiction (Manchikanti and Singh, 2008).
Despite some fears, physicians began to apply their experience in palliative care to the
treatment of chronic non-cancer pain, creating a paradigm shift that led to the promotion
and permissive use of opioids for the treatment of chronic pain in the U.S. (Ballantyne,
2012).
One in five Americans is prescribed an opioid medication each year (CCOME
presentation; data from Stobbe, 2009). Addiction and diversion (the use of prescription
drugs for recreational purposes) of prescription pain medications are critical public
health issues in the United States today, but, for many, these medications effectively
6treat pain and improve quality of life (Okie, 2007). Due to the growing knowledge of
adverse consequences related to the medical use of opioids, physicians in the United
States are increasingly faced with the dilemma of prescribing medications that have the
potential for abuse and diversion along with the possible under-treatment of pain in their
patients (Manchikanti, 2005). Patients using these drugs often have a combination of
painful conditions, substance abuse, and other forms of mental illness (Paulozzi, Weisler
and Patkar, 2011). These medications are used in the treatment of cancer and non-cancer
pain. In a study about opioid use in the treatment of long-term non-cancer pain,
Boudreau et al., found that the most common diagnoses at index visit (first RX in 6
months) were back pain, extremity pain, and osteoarthritis (Boudreau et al., 2009).
Retail sales of opioid medications increased dramatically from 1997-2005
(Manchikanti, 2007). Since 1990, medical use increased by a factor of 10. This
increase was in part influenced by the approval and aggressive marketing of Oxycontin,
an extended release form of oxycodone (Okie, 2007). Retail sales of opioid medications
increased a total of 127% between 1997 and 2006 when the total amount of commonly
utilized opioids (methadone, oxycodone, fentanyl base, hydromorphone, hydrocodone,
morphine, meperidine and codeine) increased from 50.7 million grams in 1997 to 115.3
grams in 2006. The increase was most significant for methadone (1177%) and
oxycodone (732%) (Manchikanti and Singh, 2008). During the same time period,
milligram per person use in the US increased from 73.59 mg to 329.23 grams, a 347%
increase (the mg/person increase was 1129% and 899% for methadone and oxycodone,
respectively), evidence that the quantity and dose is increasing. By 2010, over 200
million opioid prescriptions were recorded, enough to medicate every American adult
7around-the-clock for a month (Dobbs and Byers, n.d.; CDC, 2012). In comparison, the
number of prescriptions for stimulants increased from 4 million in 1991 to 45 million in
2010. Aggressive marketing by pharmaceutical companies and the social perception
that the drugs are acceptable may be additional factors driving these increases (Dobbs
and Byers, NIH, 2011).
A study conducted by Boudreau et al. of patients prescribed COT for non-cancer
pain, revealed that not only is long-term therapy increasingly prevalent, but the
concurrent use of opioids and sedative-hypnotics (i.e. valium) is unexpectedly common
(Boudreau et al, 2009). Risk of fatal or nonfatal opioid overdose may be higher among
those prescribed the medication when compared to those who obtain medicine through
diversion. A study demonstrated the risk of overdose among persons not being treated
with opioids to be 0.04% per year and 0.22% among those being treated (Ballantyne,
2012).
Non-medical Use
While many people take pain analgesics under medical management for the
treatment of acute or chronic pain, non-medical use, the use of the medication in a
manner not prescribed by a doctor or the use for non-medical purposes, is also a
concern. Non-medical use of prescription pain relievers is likely an important driving
factor of the epidemic of prescription drug overdose.
Nonmedical use of a prescription drug is defined as taking a higher-than-
recommended dose, taking a drug prescribed for another person, drug facilitated assault,
or documented misuse or abuse (DAWN, CDC 2010). The highest rate of nonmedical
use of pain relievers has been observed in the 18 to 25 year age group. In a study
8conducted in 2005 by Manchikanti et al., males were more likely than females to have
used a prescription type pain reliever non-medically in the past year (5.2 vs. 4.4%,
respectively), however among youths aged 12 to 17, females were more likely than
males to have used pain medication non-medically in the past year (7.9 vs 6.8%,
respectively) (Manchikanti, 2007).
Diversion
Diversion is defined as the unlawful transfer of a drug from a legal to an illicit
distribution network. A qualitative study conducted from 2008-2009 in Florida
identified diversion as one of six problem areas contributing to the increase in
prescription drug abuse in the state. This study showed that pain clinics played a
prominent role in the diversion of narcotic analgesics, sedatives and anti-anxiety
medications (Rigg, March, and Inciardi, 2010). According to Frank Falco of the
American Society of Interventional Pain Physicians (ASIPP) 80% of Americans aged 12
to 20 have used a controlled substance that was prescribed for someone else (Holmes,
2012). Sources of prescription drugs for illicit use include pill mills, fraud, internet
sales, and doctor shopping; however, overwhelmingly friends and family that had been
prescribed the medicine from a prescriber are the source of prescription drugs (McLeod,
2012). According to a U.S. Department of Health and Human Services (HHS) survey,
70% of abusers obtained prescription drugs illegally from friend or relative either for
free, by purchasing them or by stealing them (McLeod, 2012), highlighting the need for
programs and education about safe disposal of left-over drugs. The diversion of some
opioids to abusers may be a growing problem, given that the frequency of medical
9examiner reports of oxycodone and fentanyl in the Drug Abuse Warning Network
(DAWN) system are increasing even faster than sales of those drugs (Paulozzi, 2006).
Epidemiology
Trends in Substance Abuse
Prescription drugs are highly associated with current (past month), chronic and lifetime
drug abuse. According to the Substance Abuse and Mental Health Services
Administration’s (SAMHSA) 2013 National Survey on Drug Use and Health (NSDUH),
9.4 percent of the U.S. population aged 12 and older were current illicit drug users.
Illicit drugs include marijuana, cocaine, heroin as well as prescription-type
psychotherapeutics or prescription pain relievers, tranquilizers, sedatives and stimulants
used for non-medical purposes. In addition, the survey showed that 2.8 million people
age 12 and older used an illicit drug for the first time in 2013; of these, prescription
drugs were the second most common type of drug used on initiation after marijuana at
1.5 million new users, a slight decrease from the number observed between 2002 and
2012 (SAHMSA, 2014). Eighty percent of Americans between the ages of 12 and 20
have used a controlled substance not prescribed for them (Holmes, 2012). Every year
since 2002, 2.5 to 2.8 million Americans have abused prescription drugs for the first
time, outpacing all drugs except marijuana (Carnevale, 2012; CCOMCE 2013;
SAMHSA, NSDUH 2008).
Trends in Mortality
Trends in overdose mortality highlight this pressing public health problem.
Although deaths related to opioid analgesics could not be studied until a new coding
scheme was implemented in 1999, evidence as early as 1995, when opioid prescribing
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was just beginning to increase, demonstrate an increase in the drug overdose death rate
(Ballantyne, 2012). New codes enhanced surveillance data as they allowed for more
specific data about drugs involved in poisonings to be analyzed. The rate of overdose
mortality increased sharply in the United States in the decade between 1999 and 2007,
when the rate of unintentional overdose death in the United States increased by 124%.
This increase is thought to be largely because of increases in prescription opioid
overdoses (Bohnert, 2011). Rates of overdose deaths involving prescription drugs
increased rapidly in the United States during 1999-2006 (CDC, 2010). In 2007, CDC
reported that approximately 27,000 unintentional drug overdoses occurred in the United
States, equating to one death every 19 minutes (CDC, 2012). In 2009, more than 15,500
people died in the U.S., four times the number in 1999 (McLeod, 2012). Indeed, deaths
by poisonings (90% of them cause by drug overdoses) surpassed motor vehicle crashes
several years ago as the most common cause of accidental death in many states in the
U.S. (Okie, 2011).
Morbidity
Around the same time overdose deaths were observed to rise sharply, emergency
visits from opioid overdoses multiplied (Ballantyne, 2012). Findings from a study
conducted in 2010 by CDC and SAMHSA demonstrate a substantial increase in drug
related (DR) morbidity as well. In a review of drug related hospital emergency
department data from 2004-2008, researchers observed an estimated 111% increase in
ED visits for nonmedical use of opioid analgesics during the study period and an 89%
increase in visits associated with nonmedical use of benzodiazepines (SAMHSA, 2010).
For every unintentional DR overdose death, nine persons are admitted for substance
11
abuse treatment, 35 visit emergency departments, 161 report drug abuse or dependence,
and 461 report nonmedical uses of opioid analgesics (CDC, 2012). Visits to emergency
departments for opioid abuse more than doubled between 2004 and 2008, substance
abuse treatment program admissions increased by 400% between 1998 and 2008.
Among these admissions, prescription painkillers were the second most prevalent type
of abused drug after marijuana (Okie, 2010).
Risk Groups
The National Center for Health Statistics (NCHS) reported that between 2000
and 2010, the death rate per 100,000 population increased for males and females, all
race/ethnicity groups and all ages (CDC-NCHS, 2012). Overall, rates of opioid misuse
and overdose deaths are highest among men, persons aged 20-64 years, American
Indians/Alaskan Natives and non-Hispanic whites, persons with mental illness and poor
and rural populations (JAMA, 2012).
Females were observed to have a higher rate of increase (130%) than males
(80%); however the age-adjusted death rate among males (15.0) was 1.5 times higher
than females (9.6). Among all drug poisoning deaths, age adjusted death rates were
highest among American Indians/Alaskan Natives (16.8), followed by non-Hispanic
whites (15.7), non-Hispanic blacks (8.0), Hispanics/Latinos (5.6) and Asian/Pacific
Islanders (1.9) (CDC-NCHS, 2012). With regard to age, NCHS reports that since 2004,
the drug poisoning death rate has been highest among 45-54 year olds; however,
between 2009 and 2010, the largest age-specific increase was among adults age 55-64
years (CDC-NCHS, 2012). Poisonings among this age group are most concerning
because this is the fastest growing segment of the population in the United States.
12
Persons who a have mental illness are overrepresented among those who are
prescribed opioids and those who overdose on them (CDC, 2012). Psychotropic drugs
such as benzodiazepines are used in the management of persons with diagnosed mental
health disorders. Benzodiazepine-based tranquilizers contributed to 48.8% of
prescription overdose deaths in West Virginia in 2006. Of decedents whose deaths
involved benzodiazepines, 46.3% did not have a previous prescription for the drug
(Toblin et al., 2010). These data indicate that prescription of benzodiazepines to treat
mental illness may be a significant risk factor contributing to the rising incidence of
drug-related poisonings.
Region
The overall age-adjusted drug poisoning death rate in 2010 was 12.3 deaths per
100,000 population. Rates varied widely by state with the lowest rate observed 3.4 in
North Dakota to the highest in West Virginia (28.9). Per capita opioid sales and death
rates vary widely among the 50 states. Studies have found a strong correlation between
drug-poisoning mortality and opioid consumption; per capita sales are most strongly
linked with methadone- and oxycodone- related mortality (Okie, 2010). Nevada was
among the five states with the highest death rates at 20.7 per 100, 000 population.
Initially, the increase in fatal prescription drug overdoses was observed in rural areas
and rural states. Rural areas also observed the sharpest increase in admissions for
substance abuse treatment for narcotic pain medication addiction (Paulozzi, 2006). By
2002, opioid analgesics were involved in more deaths than illicit drugs traditionally
known to be problematic in urban areas like heroin and cocaine (Paulozzi, 2006).
Admissions data analyzed from DAWN showed a similar trend - with opioid related
13
admissions increasing 101.4%, and heroin and cocaine related visits increasing 32.2%
and 23.7% respectively (Paulozzi, 2006).
Drug Type
Reviews of mortality data reveal that in many cases of fatal poisoning, multiple
substances are present (North Carolina Center for Health Statistics, 2007). The most
frequent combination is an opioid pain analgesic along with a benzodiazepine. Alcohol
is also often involved. Recent studies have shown that methadone may be an emerging
problem. Methadone is an opioid generally used in the treatment of substance abuse
related to heroin; however, data show its use in pain management and its role in drug-
related (DR) mortality is becoming more prevalent. In a study conducted by Paulozzi et
al., (2009), of mortality data in West Virginia from 2006, overdose deaths related to
methadone were observed to be more prevalent in younger age group (> 25% were in
the 18-25 year range) and less likely to have ever been prescribed. In 2007, researchers
in North Carolina noted that methadone contributed to over 1/3 of fatal poisonings
observed that year.
Long term Use and Dose
Pain, sometimes described as the “fifth sense” (Boudreau et al., 2009), has
recieved much closer attention in the recent past as an indicator of health and wellbeing.
Chronic non-cancer pain is a contributing factor in the growing problem of prescription
overdose. Opioid analgesics were approved for widespread use in the treatment and
control of chronic pain in the 1990s. There is some evidence that higher prescribed
doses increase the risk of drug overdose among individuals treated with opioids for
chronic non-cancer pain. Specifically, the risk of drug-related adverse events is higher
14
among individuals prescribed opioids at doses equal to 50 mg/d or more of morphine
(Bohnert, 2001). Boudreau found that long term users tend to use opioid analgesic with
sedative hypnotic medication (Boudreau et al., 2009). According to CDC the two most
at-risk groups are 1) long term medial users (reportedly 9 million) and 2) non-medical
users of opioids who report past month use (reportedly 5 million).
The Cost of Prescription Drug Abuse
In addition to the epidemiological cost of prescription drug use and abuse, there
are significant associated economic costs. Total economic costs include workplace,
healthcare and criminal justice expenditures. In 2001 the total economic burden was
estimated to be $8.6 billion. Per capita annual direct health care costs from 1998 to2002
were nearly $16, 000 for abusers of prescription and nonprescription opioids and $1,800
for nonusers with at least one prescription insurance claim (Strassels, 2009). A 2011
study estimated the total non-medical cost to be $53.4 billion - comprised of $42 billion
due to loss of productivity, $8.2 billion to criminal justice costs, $2.2 billion to drug
abuse treatment and $944 million to medical complications (McLeod, 2012). Many
health and social problems are related to this epidemic. For example, New York is
experiencing a record number of overdoses, suicides, new addictions, and armed
pharmacy robberies, some of which have resulted in casualties (Hannon, et al. New
York)
Prescription Drug Poisoning in Nevada
Trends in Substance Abuse
According to data from NSDUH, Nevada has observed one of the highest rates
of drug use and abuse in the United States. In 2007-2008, approximately 9% of Nevada
15
residents reported illicit drug use during the past-month. Nevada was among the top ten
states for high rates in several drug-use categories. Among these categories were past-
year non-medical use of pain relievers among persons age 12 and older and among
young adults 18-25. Nevada was also among the top ten states for past-month illicit
drug use among persons age 12 years and older (ONDCP, 2011). Additionally,
Nevadans report a higher rate of using illicit drugs other than marijuana in the past
month. Stimulants are the most commonly cited drugs among primary drug treatment
admissions in Nevada.
Mortality Trends
In 2012, Nevada had the 4th highest drug overdose mortality rate (20.7 per
100,000 population) in the nation. An analysis of prescription drug overdose deaths in
Clark County between 2000 and 2011 revealed the age adjusted death rate was 70%
higher in Clark County than the national average (Feng & Middaugh, 2013).   In 2007,
515 deaths were attributed to drug use. In the same time period 407 persons died from
motor vehicle accidents and 414 due to firearms.
In an analysis conducted by the Southern Nevada Health District (2013) of
mortality data from 2000 to 2011, they found that the mortality rate of fatal poisonings
nearly doubled during that time period, accounting for 38% of all injury deaths. Of
these, 80% were attributed to prescription drugs. Between 2009 and 2011, poisoning
surpassed firearms as the leading cause of injury death in Clark County, accounting for
38% of all injury deaths (Feng & Middaugh, 2013). More than eight of every ten DR
deaths in Clark County involved opioids or other narcotics; two-thirds involved opioid
analgesics. The highest rate of DR mortality was among 45-54 year olds. Males had the
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majority of the overall number of DR deaths, but rates increased significantly for both
males and females, with females comprising 56% of the DR deaths involving synthetic
narcotics (excluding methadone). Benzodiazepines were involved in 24% of DR deaths;
combination drug use, where an opioid or other narcotic was present with a
benzodiazepine, was identified in 22% of all deaths. Use of an opioid with another
depressant like alcohol was documented in 9% of deaths.
Findings from the Clark County Office of the Coroner and Medical Examiner
show a similar trend. Among the 14,995 deaths investigated by CCOCME, in 2012, 331
of 522 accidental deaths were attributed to prescription drugs. Additionally, CCOCME
reported that in 2012, the number of drug related deaths due to prescription medication
(72.5%) was 3 times greater than the rate of illicit street drug related deaths (Clark
County observed a 30% decrease in OD deaths related to street drugs during this time
period). Additional trends observed by CCOCME during this time were polydrug use
(average of 4 different substances/compounds), predominance of
oxycodone/oxymorphone, methadone, and morphine, and a 700% increase of accidental
prescription drug and alcohol related deaths in the past 10 years in individuals over 60
years old (CCOCME, 2014).
To date, no study has been done to describe the morbidity of prescription drug overdose
cases diagnosed at hospitals within Clark County, Nevada.
17
CHAPTER 3
STUDY DESIGN
Study Design
This study was a population based retrospective case series analysis of hospital
discharges related to prescription drug poisonings (DP) associated with opiates and
related narcotics, antidepressants, sedatives and tranquilizers for hospitals in Clark
County, Nevada between 2009 and 2013.
Discharge data were obtained from the Center for Health Information Analysis
(CHIA), a research center at the University of Nevada, Las Vegas within the School of
Community Health Sciences. CHIA receives hospital discharge data, ambulatory
surgical center and public transparency in health data on a monthly or quarterly basis.
Reporting is mandated by state law (AB146). The mission of the Center for Health
Information Analysis (CHIA) is to act as a central health data hub for Nevada, in an
effort to improve data quality and increase available knowledge via public transparency
works. To this end, they collect emergency room and hospital discharge data. CHIA
data are compliant with the Health Insurance Portability and Accountability Act
(HIPAA). All researchers using CHIA data for this study have an approved Limited
Data Set Use Agreement (LDSUA) as required. For the purpose of this study, both
hospital inpatient and outpatient data were used.
Research Questions
1. What was the trend in prescription drug poisoning admissions in Clark County,
Nevada between 2009 and 2013?
H1: The rate of drug related hospitalizations increased between 2009 and 2013
among all demographic groups.
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Method: Count and rate calculations were generated for each age, gender, race
using population estimates from the American Community Survey.
2. What were the characteristics of prescription drug poisoning cases in Clark
County between 2009 and 2013?
H1: Males will represent the majority of the overall DP cases.
H2: Among persons age 20 – 35, the number of females will be higher.
H3: Non-Hispanic whites have the highest incidence of prescription drug related
admissions.
Method: Descriptive statistics were utilized to describe characteristics of drug
poisoning admissions. Frequencies and rates were calculated for each selected
demographic characteristic.
3. What were the most common drugs related to overdose admissions in Clark
County, Nevada?
H1: Opioids are the most common contributory drug type associated with
prescription drug poisoning admissions.
H2: Most DP admissions will involve multiple drugs (including alcohol).
Method: Frequencies were calculated for drug poisoning type indicated in the
primary diagnosis and for each commonly identified drug combination including
any drug and alcohol.
4. What are the characteristics of repeat overdose case?
H1: Repeat cases will be more likely to be young, female.
H2: The greatest number of repeat cases will be persons older than 60 years.
Method: Descriptive statistics were utilized to describe characteristics of drug
poisoning admissions. Frequencies and rates were calculated for each selected
demographic characteristic.
5. What characteristics predict that alcohol will be involved in a drug poisoning?
H1: Male gender will increase odds when compared to females.
H2: Persons age 35-44 and 45-64 will have higher odds of alcohol involvement.
H3: Single status will increase the odds when compared to other marital status
categories persons.
H4: Medicaid and uninsured payer source will increase odds when compared to
private insurance.
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Method: Binary logistic regression was used to test relationship between
demographic characteristics of gender, age, marital status and payer source
against a reference a group to identify predictors of alcohol involvement in drug
poisonings.
6. What characteristics predict that multiple contributory drugs will be involved in a
drug poisoning?
H1: Female gender will increase odds of a drug poisoning involving multiple
drugs.
H2: Public payer source will increase odds of a DP involving multiple drugs.
H3: Age and marital status will have no effect on the odds of DP involving
multiple drugs.
Method: Binary logistic regression was used to test relationship between
demographic characteristics of gender, age, marital status and payer source
against a reference a group to identify predictors of combination/multiple drug
use in drug poisoning admissions.
7. What characteristics predict a person will have repeat poisoning admissions?
H1: Female gender will predict a multiple admission.
H2: Age 45-64 will predict a multiple admission.
H3: Public payer type will increase odds of a multiple admission.
Method: Binary logistic regression was used to test relationship between
demographic characteristics of gender, age, marital status and payer source
against a reference a group to identify predictors of multiple DP admissions in a
given year.
Case Selection
Drug Poisoning Case
We identified all hospital admissions (inpatient and emergency department) related
to unintentional prescription drug poisonings that occurred in Clark County, Nevada
between 2009 and 2013. Cases were found by querying hospital discharge data from the
Center for Health Information Analysis for the appropriate International Statistical
Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes. Cases were
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included if the admission listed a primary diagnosis of drug poisoning by one of four
major drug categories of interest as follows:
Ȉ Poisoning by methadone
Ȉ Poisoning by opiates and related narcotics
Ȉ Poisoning by antidepressants, sedative-hypnotics, tranquilizers
Ȉ Poisoning by benzodiazepine-based tranquilizers
and an Supplementary Classification of External Causes of Injury and Poisoning
external cause of injury code (E-code) suggesting the poisoning was accidental (Table
1).
The principal diagnosis generally represents the primary reason for the health
care contact. For hospitalizations, the principal or primary diagnosis is the condition
established at the end of the hospitalization to be chiefly responsible for occasioning the
admission of the patient to the hospital for care. In the case of ED visits, the principal or
primary diagnosis code is the diagnosis established to be chiefly responsible for
occasioning the ED visit. Unintentional poisonings are poisonings in which individuals
exposed to the substance did not attempt to cause harm to themselves or others. The
range of codes specific to unintentional poisonings are E850-E858 (Unintentional
Poisoning by Drugs, Medicinal Substances, and Biologicals) and E860-E864 and E866-
E869. Unintentional drug poisonings are classified according to E-codes 850-858.
(Harmon, 2010) Poisoning determined to be intentional or those where intent is
undetermined are coded accordingly.
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Table 1. Diagnosis and External Cause of Injury Codes Related to Unintentional
Prescription Drug Poisoning by Select Drug Type
Drug Category Diagnosis Codes
(ICD-9)
Corresponding
E-codes
Opiates and related narcotics 965.00, 965.03-09 E850 (.1-.2)
Methadone 965.02 E850.1
Antidepressants, sedative-
hypnotics (includes
barbituates, tranquilizers,
other psychotropic agents)
966, 967, 969, 970 (E851-E853, E854 (.0
- .2, .8), E855.0)
Benzodiazepines 969.4 E853.2
Codes for opium (965.00) and heroin (965.01) were excluded from this analysis.
Drug poisonings involving illicit drugs, non-opioid painkillers, and certain stimulants
were not included. Also excluded were poisonings that listed excessive alcohol
consumption as primary cause of injury even where E-codes indicating unintentional
drug poisoning were present.
The case selection methodology closely follows the recommendations suggested
by the Safe States Injury Surveillance Workgroup’s Consensus Recommendations for
National and State Poisoning Surveillance (Safe States, 2012).
Repeat Case
CHIA uses a probabilistic data linking method to generate a unique patient
identifier (PUID) to identify multiple hospital encounters over a 15 month period. The
PUID was used to identify repeat cases in order to compare characteristics of repeat
cases to single incident cases in each of the five years for which the study was
conducted. A repeat case was counted if there were 2 or more admissions for the same
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person within a calendar year in the respective inpatient or emergency department data
set. Cases could not be tracked across inpatient and ED data due to limitations of the
data tracking system.
Statistical Analysis
Statistical methods were primarily descriptive. Demographic characteristics of
age, gender, race/ethnicity, marital status and payer type were analyzed. Age and sex
standardized incidence rates were calculated using county-level population estimates
from the American Community Survey for the corresponding study year. The overall
and gender-specific rates were calculated as a weighted number of discharges per
100,000 population in each age grouping. Ages were grouped as follows: 18-24, 25-34,
35-44, 45-64, and 65 and older. Additionally, race/ethnic group specific rates were
calculated per 100,000 population. Counts and frequencies were then tabulated to
determine the characteristics of persons that who had a drug poisoning encounter. The
distribution of each characteristic was calculated. Comparisons were made between
groups of different demographic categories.
Zip code of residence was used to examine the burden of drug poisonings of
residents compared to visitors. As a proxy for socio economic status, payer source was
used.
Contributory drugs were identified by using the specific ICD-9 code listed as a
primary diagnosis plus any listed E-codes. Counts and percentages were calculated to
demonstrate the frequency of each drug category in drug poisoning admissions using the
primary diagnosis code.
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Logistic regression and chi square analysis were utilized to calculate odds ratios
for repeat cases, drug plus alcohol use and multiple drug use based on descriptive
characteristics. Odds ratios identified descriptive characteristics that were associated
with increased risk or that were protective.
Statistical significance was defined as a p value of < .05. Groups with rates
significantly above or below the overall rate were identified.
Software
Statistical Package for the Social Sciences (SPSS) Version 22.0 was used to
conduct all analyses.
Human Subjects Consideration
This study was a granted an exemption from the UNLV Institutional Review Board.
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CHAPTER 4
RESULTS
Trends in Pharmaceutical Drug Poisoning Clark County 2009-2013
The number of admissions for a prescription drug poisoning involving
methadone, opiates or other related narcotics, antidepressants and benzodiazepines are
shown in Table 2. Between 2009 and 2013 there were 7414 admissions to Clark County
hospitals with a primary diagnosis of an unintentional poisoning due to a prescription
drug. Of these, 2742 were inpatient admissions and 4672 were emergency department
visits. Inpatient admissions increased between 2009 and 2013. Emergency department
visits remained relatively stable throughout the five- year study period. The overall
number of inpatient and emergency department discharges with diagnostic codes
indicating unintentional drug overdose increased from 1368 in 2009 to 1450 in 2013,
with peak incidence in 2011 (n=1609). The epidemic curve is displayed in Figure 1.
Table 2. Number of Admissions for Prescription Drug Poisoning by Year and by
Admission Type
Admission Type
Total by YearIP ED
Discharge Year
2009 471 897 1368
2010 469 999 1468
2011 602 1007 1609
2012 611 908 1519
2013 589 861 1450
Total by Admission
Type 2742 4672 7414
IP=inpatient admission ED=emergency department admission
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Figure 1. Epidemic Curve – Drug Poisoning Admissions Involving Select Prescription
Drugs – Methadone, Opioids, Antidepressants, Benzodiazepines – at Clark County,
Nevada Hospitals 2009-2013
Characteristics of Admissions for Unintentional Pharmaceutical Drug Poisonings
Characteristics of persons admitted for an unintentional pharmaceutical drug
poisoning are described in Table 3. The demographic characteristics were similar in all five
study years and between inpatient and emergency department admissions (See Tables 4-6).
Gender
In each year of the study women represented slightly over half of all admissions.
The average overall admissions rate for the five year study period among females was
85.23 per 100, 000 compared to 65.37 per 100, 00 males (Figure 2 & 3).
Age
The greatest percentage of admissions occurred among persons 35 to 64 years
old. Rates among younger age groups (18-24 and 25-34) were higher in 2009 and 2010
as shown in Figure 4. Admission rates increased among persons age 65 and older. The
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difference in admissions between males and females was most substantial in the 45-64
year old age group. The distribution of admissions by age and gender for each year is
displayed in Figure 2.
Figure 2. Annual Distribution of Prescription Drug Poisoning Admissions by Age and
Gender, Clark County, Nevada 2009-2013
Race
Non-Hispanic whites accounted for the largest percentage (five year average
>75.12%; range 71.1 to 77.7%) of all drug poisoning admissions among inpatient and
emergency department discharges for all years analyzed. The most significant rate
increase was observed among Native American/Alaskan Native subgroup where rates
increased sharply between 2012 and 2013 from 13 to 120 Per 100,000 population
(Figure 5). It is important to note that this result may be a result of the small sample size
of Native Americans in our population.
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Marital Status
Single persons accounted for 45% of inpatient admission and most of the
admissions during the study period.
Payer Source
Uninsured was the most frequent (38.5%, n=2856) payer type associated with
drug poisoning admissions. Uninsured was a categorical group comprise of self-pay,
charity and indigent payer sources. Medicare and Medicaid were also common and
combined these public payer types comprised 34.5% of all admissions combined.
Private insurance payers accounted for 23.3% and of admissions. Veterans
Administration insurance was the payer source in only 1.6% of DP admissions.
Residence
Over 90% of all admissions were persons with residences within Clark County.
Zip codes with high incidence of inpatient admission were 89101, 89108 and 89121.
Among ED admissions, zip codes with incidences over 100 included 89101, 89108,
89103, 89117, 89014, 89015, 89103, 89104, 89110, 89119, 89121, 89122, and 89123.
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Table 3.  Characteristics of Drug Poisoning Admissions, Clark County Hospitals, 2009-2013 
 
  2009 2010 2011 2012 2013 
  IP ED IP ED IP ED IP ED IP ED 
  N % N % N % N % N % N % N % N % N % N % 
Characteristic                                         
Total  471 100.00 897 100.00 469 100 999 100.00 602 100 1007 100 611 100.00 908 100.00 589 100.00 861 100.00 
Gender 
Male 213 45.22 371 41.36 231 49.25 442 44.24 286 47.51 450 44.687 262 42.88 385 42.40 263 44.65 343 39.84 
Female 258 54.78 526 58.64 238 50.75 557 55.76 316 52.49 557 55.313 349 57.12 523 57.60 326 55.35 518 60.16 
Age 
18-24 43 9.13 154 17.17 39 8.316 171 17.12 63 10.47 153 15.194 33 5.40 28 3.08 31 5.26 120 13.94 
25-34 84 17.83 203 22.63 65 13.86 215 21.52 80 13.29 255 25.323 83 13.58 222 24.45 84 14.26 199 23.11 
35-44 105 22.29 195 21.74 91 19.40 230 23.02 124 20.6 200 19.861 97 15.88 185 20.37 88 14.94 177 20.56 
45-64 172 36.52 295 32.89 207 44.14 331 33.13 245 40.70 338 33.565 292 47.79 303 33.37 264 44.82 285 33.10 
65+ 67 14.23 50 5.57 67 14.29 52 5.21 90 14.95 61 6.0576 106 17.35 70 7.71 122 20.71 80 9.29 
Race/Ethnicity 
Hispanic  48 10.19 97 10.81 45 9.595 110 11.01 48 7.973 113 11.221 53 8.67 128 14.10 38 6.45 85 9.87 
NH White 366 77.71 619 69.01 357 76.12 723 72.37 455 75.58 702 69.712 459 75.12 615 67.73 419 71.14 574 66.67 
NH Black 32 6.79 112 12.49 41 8.74 111 11.11 56 9.30 124 12.314 48 7.86 99 10.90 61 10.36 102 11.85 
Native 
American 
3 0.64 5 0.56 2 0.43 0 0.00 1 0.167 1 0.0993 1 0.16 3 0.33 12 2.04 20 2.32 
Asian 9 1.91 29 3.23 12 2.56 18 1.80 12 1.99 26 2.5819 15 2.45 32 3.52 15 2.55 22 2.56 
Marital Status 
Single 228 48.41 513 57.19 217 46.27 545 54.55 299 49.67 546 54.22 249 40.75 478 52.64 233 39.56 434 50.41 
Married/Life 
Partner 
157 33.33 244 27.20 144 30.70 306 30.63 177 29.40 324 32.175 236 38.63 275 30.29 233 39.56 267 31.01 
Divorced 44 9.34 87 9.70 63 13.43 97 9.71 75 12.46 95 9.434 65 10.64 94 10.35 65 11.04 92 10.69 
Legally 
Separated 
6 1.27 21 2.34 6 1.27 15 1.50 5 0.83 9 0.8937 11 1.80 26 2.86 12 2.04 22 2.56 
Widow 21 4.46 14 1.56 23 4.90 24 2.40 35 5.81 29 2.8798 43 7.04 30 3.30 34 5.77 34 3.95 
Payer Type 
Private 96 20.38 247 27.54 79 16.84 252 25.23 127 21.10 256 25.422 112 18.33 250 27.53 110 18.68 199 23.11 
Medicaid 88 18.68 76 8.47 89 18.98 106 10.61 105 17.44 128 12.711 97 15.88 110 12.11 100 16.98 108 12.54 
Medicare 114 24.20 110 12.26 128 27.29 142 14.21 171 28.41 148 14.697 202 33.06 171 18.83 217 36.84 169 19.63 
VA/Champus 5 1.06 18 2.01 3 0.64 21 2.10 3 0.498 19 1.8868 12 1.96 9 0.99 15 2.55 16 1.86 
Uninsured 165 35.03 405 45.15 161 34.3 470 47.05 185 30.73 438 43.496 179 29.30 359 39.54 144 24.45 350 40.65 
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Table 4.  Rate of Overall Admissions for Unintentional Prescription Drug Poisoning by Select Characteristics, Clark County, 
NV Hospitals 2009-2013 
 
 2009 2010 2011 2012 2013 
Characteristic 
N Rate N Rate N Rate N Rate N Rate 
Total  1368 71.89 1468 75.12 1609 82.33 1519 75.92 1450 71.50 
Gender 
Male 584 60.36 673 68.34 736 45.39 647 64.34 606 59.57 
Female 784 83.82 795 82.00 873 56.91 872 87.62 844 83.51 
Age 
18-24 197 120.38 210 116.80 216 84.42 161 87.47 151 81.83 
25-34 287 95.37 280 95.00 335 86.70 305 102.78 283 94.70 
35-44 300 106.68 321 111.57 324 69.81 282 97.74 265 91.85 
45-64 467 103.14 538 111.64 583 69.14 595 119.96 549 108.58 
65+ 117 57.48 119 53.68 151 26.42 176 71.62 202 77.65 
Race/Ethnicity 
Hispanic 145 26.02 155 27.14 161 19.34 181 30.36 123 20.23 
White 985 68.11 1080 77.59 1157 50.47 1074 78.95 993 74.07 
Black 144 68.48 152 66.53 180 53.01 147 59.75 163 65.02 
Native 
American 
8 29.11 2 25.61 2 3.57 4 13.00 32 120.74 
Asian 
(includes 
Hawaiian/PI) 
38 19.90 30 16.61 38 10.85 47 18.98 37 14.21 
Rate per 100,000 population. Rates calculated based on population estimates from American Community Survey for each corresponding year.  
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Table 5.  Rates of Inpatient Admissions for Unintentional Prescription Drug Poisoning by Select Characteristics Clark County, 
Nevada 2009-2013 
Rate per 100,000 population; Rates calculated based on population estimates from American Community Survey for each corresponding year.  
 
  
  2009 2010 2011 2012 2013 
Characteristic N Rate N Rate N Rate N Rate N Rate 
Total  471 24.75 469 24.00 602 30.56 611 30.54 589 29.05 
Gender 
Male 213 22.01 231 23.46 286 28.85 262 26.02 263 25.85 
Female 258 27.58 238 24.55 316 32.29 349 35.07 326 32.26 
Age 
18-24 43 26.28 39 21.69 63 34.76 33 17.93 31 16.8 
25-34 84 27.91 65 22.05 80 27.20 83 27.97 84 28.11 
35-44 105 37.34 91 31.63 124 43.28 97 33.62 88 30.5 
45-64 172 37.99 207 42.95 245 50.12 292 58.87 264 52.22 
65+ 67 32.91 67 30.22 90 38.98 106 43.14 122 46.89 
Race/Ethnicity 
Hispanic 48 8.61 45 7.88 48 8.21 53 8.89 38 6.25 
White 366 25.31 357 25.65 455 32.71 459 33.74 419 31.25 
Black 32 15.22 41 17.94 56 23.94 48 19.51 61 24.33 
Native American 3 10.91 2 25.61 1 3.57 1 3.25 12 45.28 
Asian  
(includes Hawaiian/PI) 
9 4.71 12 6.64 12 5.00 15 6.06 15 5.76 
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Table 6.  Rates of Emergency Department Admissions for Unintentional Prescription Drug Poisoning Select Characteristics 
Clark County, Nevada 2009-2013 
 
 2009 2010 2011 2012 2013 
Characteristic N Rate N Rate N Rate N Rate N Rate 
Total  897 47.14 999 51.11 1007 51.12 908 45.38 861 42.46 
Gender 
Male 371 38.35 442 44.88 450 45.39 385 38.29 343 33.72 
Female 526 56.24 557 57.45 557 56.91 523 52.55 518 51.26 
Age 
18-24 154 94.01 171 95.11 153 84.42 128 69.54 120 65.03 
25-34 203 67.55 215 72.95 255 86.7 222 74.81 199 66.59 
35-44 195 69.34 230 79.94 200 69.81 185 64.12 177 61.35 
45-64 295 65.15 331 68.69 338 69.14 303 61.09 285 56.37 
65+ 50 24.56 52 23.46 61 26.42 70 28.49 80 30.75 
Race/Ethnicity 
Hispanic 97 17.41 110 19.26 113 19.34 128 21.47 85 13.98 
White 619 42.8 723 51.94 702 50.47 615 45.21 574 42.81 
Black 112 53.26 111 48.58 124 53.01 99 40.24 102 40.69 
Native American 5 18.2 0 0 1 3.57 3 9.75 20 75.46 
Asian (includes 
Hawaiian/PI) 
29 15.19 18 9.97 26 10.85 32 12.92 22 8.45 
Rate per 100,000 population; Rates calculated based on population estimates from American Community Survey for each corresponding year.  
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Figure 3.  Unintentional Prescription Drug Poisoning Admission Rates by Gender – 
Total Admissions 2009-2013 
 
 
 
 
Figure 4.  Unintentional Prescription Drug Poisoning Admission Rates by Age – Total 
Admissions 2009-2013 
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Figure 5.  Unintentional Prescription Drug Poisoning Admission Rates by Race/Ethnicity 
– Total Admissions 2009-2013 
 
 
Drug Type 
Benzodiazepines and opioids (including related narcotics) were the most 
prevalent drug categories listed as the primary diagnosis in prescription drug poisoning 
admissions during the study period (Table 7 & Table 8, Figure 6 & Figure 7).  
Benzodiazepines were involved in 49% of all admissions and listed as the primary 
diagnosis category in 45% admissions.  When compared to males, females had 38% 
greater odds (OR=1.38, 95% CI 1.25 to 1.51, p<.0001) of having benzodiazepine listed as 
the primary contributory drug.  Opioids and other related narcotics were the second most 
common drug type listed as a primary diagnosis in 29% of all admissions.  More females 
had benzodiazepines and other sedatives as the primary contributory drug, while males 
represented most of the cases with methadone as the primary contributory drug.  
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methadone was very low in the 65 and older group and benzodiazepines poisonings were 
very high in the 45-64 age group.   
 
Table 7.  Number of Unintentional Prescription Drug Poisoning Admissions by Drug 
Category listed as Primary Diagnosis by Year 
  Methadone Opioids Antidepressant Benzodiazepine 
Year IP ED IP ED IP ED IP ED 
Total 
Admissions by 
Year 
2009 27 28 138 238 113 192 193 439 1368 
2010 27 31 131 287 87 187 224 494 1468 
2011 32 27 181 294 139 231 250 455 1609 
2012 30 18 186 286 153 195 242 409 1519 
2013 21 17 174 237 184 187 210 420 1450 
Total  137 121 810 1342 676 992 1119 2217 7414 
Total 
Admissions 
by Drug type 
258 (3%) 2152 (29%) 1668 (22.5%) 3336 (45%) 7414 (100%) 
 
 
 
Table 8.  Contributory Drug by Primary Diagnosis and Gender – Unintentional 
Prescription Drug Poisoning Admissions – Total Admissions, Clark County, NV 2009-
2013 
Methadone Opioids Antidepressant Benzodiazepine Total 
Female  
N 111 1185 825 2020 4141 
% between 
genders  43.0% 55.1% 51.4% 60.6% 56.3% 
 
% in 
gender 2.7% 28.6% 19.9% 48.8% 100% 
Male 
 
N 147 967 779 1316 3209 
% between 
genders 57.0% 44.9% 48.6% 39.4% 43.7% 
 
% in 
gender 4.6% 30.1% 10.6% 41.0% 100% 
Total 
 
N 258 2152 1604 3336 7350 
% of Total 3.5% 29.3% 21.8% 45.4% 100.0% 
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Figure 6.  Distribution of Primary Contributory Drug Type in Unintentional Prescription 
Drug Poisoning Admissions by Gender – Total Admissions 2009-2013 
 
 
 
Figure 7.  Distribution of Primary Contributory Drug Type in Unintentional Prescription 
Drug Poisoning Admissions by Age – Total Admissions 2009-2013 
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of all admissions overall (Table 9).  The most common drug combination found among 
poisoning admissions indicating multiple drug use was an antidepressant and a 
benzodiazepine.  The distribution of primary contributory drug type among all age 
groups, marital status, race and payer source mirrored the overall distribution.   
Alcohol Involvement 
Alcohol was involved in less than 1% of all admissions, but was twice as 
prevalent among inpatient admissions when compared to ED admissions (Table 9).  The 
majority of ED admissions were related to a drug poisoning by a single category of drugs 
(n=3075, 66%) with no alcohol.  Only 26 ED poisoning admissions had associated 
alcohol as indicated by related E-codes.  Of these 17 were poisonings due to multi-drug 
use and alcohol.  In the 65 and older age group, no poisonings were associated with 
alcohol use.   
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Table 9.  Frequency of Contributory Drugs involved in Unintentional Prescription Drug 
Poisoning Admissions, Clark County Hospitals, 2009-2013 
   
Inpatient 
% (N) 
 
ED 
% (N) 
Total 
%(N) 
Single Drug 75 (2059) 79.2 (3699) 77.6 (5758) 
Multiple Drugs* 25 (683) 20.8 (973) 22 (1656) 
Admissions by Primary 
Diagnosis Category    
Methadone 5.0   (137) 2.6 (121) 3.5 (268) 
Opiate or other narcotic 29.5 (810) 28.7 (1342) 29.0 (2152) 
Antidepressant 24.7 (676) 21.2 (992) 22.5 (1668) 
Benzodiazepine 40.8 (1119) 47.5 (2217) 45.0 (3336) 
Admissions involving Alcohol 1.6  (44) .56 (26) .94 (70) 
Admissions involving Drug 
Combinations    
Antidepressant and 
Benzodiazepine 18.5 (508) 17.3 (808) 17.8 (1316) 
Antidepressant and Opiates 8.5 (233) 5.4 (252) 6.5 (485) 
Opiate and Benzodiazepine 6.7 (185) 4.8 (200) 5.2 (385) 
Opiate and Methadone 5.2 (142) 2.6 (121) 3.5 (263) 
Methadone and Antidepressant 0.95 (26) .26 (12) .5 (38) 
Methadone and Benzodiazepine .8 (22) .17 (8) .4 (30) 
*Admissions that listed at least 2 diagnoses and/or E-codes   
 
 
Repeat Cases  
We identified 384 repeat cases among all admissions during the study period. 
Characteristics of repeat cases are displayed in Table 10.  Unlike single cases, males 
comprised the majority of repeat cases (62%).  Like single cases, poisoning by 
benzodiazepines was the most common primary diagnosis among repeat cases; the 
frequency of poisoning by antidepressants was relatively low when compared to single 
incident cases.  Repeat cases had a higher percentage of opioids as primary diagnosis.   
Alcohol was more prevalent among repeat cases when compared to single cases (11.5% 
versus .94%, respectively).  Other characteristics were similar between single and repeat 
cases.   
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Table 10.  Select Characteristics of Repeat Cases, All Admissions for Unintentional Drug 
Poisoning by Select Prescription Drugs, Clark County Hospitals, 2009-2013 
Characteristic N % Characteristic N %
Admission Type Marital Status    
Inpatient 153 39.84 Single 225 58.59
Emergency Dept. 231 60.16 Married/Life Partner 86 22.40
Total  384 100.00 Divorced 48 12.50
Admissions by Year Legally Separated 5 1.30
2009 59 15.36 Widow 11 2.86
2010 80 20.83 Payer Type
2011 104 27.08 Private 78 20.31
2012 75 19.53 Medicaid 59 15.36
2013 66 17.19 Medicare 72 18.75
Gender VA/Champus 2 0.52
Male 238 61.98 Uninsured 166 43.23
Female 146 38.02  
Age  
18-24 48 12.50  
25-34 83 21.61  
35-44 77 20.05  
45-64 157 40.89  
65+ 19 4.95  
Race/Ethnicity  
Hispanic  37 9.64  
NH White 296 77.08  
NH Black 35 9.11  
Native American 2 0.52  
Asian 1 0.26  
 
 
Predictors of Select Outcomes  
 
We used binary logistic regression to identify predictors for three outcomes:  
alcohol and drug use, multiple drug use and repeat/multiple admissions.  Regression 
results for each outcome are shown in Tables 11, 12 and 13, respectively. Significant 
values are displayed in bolded text. The dependent variable was the dichotomous yes/no 
for combined alcohol plus drugs, multiple drugs, and repeat/multiple admissions.  The 
independent variables were gender, race, marital status, payer type and age.  Because 
 39 
 
each of the independent variables was categorical, the reference categories were: male, 
white, single, private health insurance and 18-24. 
Combined Drug and Alcohol Use  
Regression results provided evidence that when compared to males, females have 
50% lower odds of having alcohol listed as an external cause of injury in drug poisoning 
admissions. Gender was the only significant predictor of alcohol use among drug 
poisoning admissions. 
 
 
Table 11.  Predictors of Alcohol Involvement in Unintentional Prescription Drug 
Poisoning Admission Cases  
B Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Gender  
Female* -.696 .006 .499 .303 .822 
Race 
Black .563 .103 1.756 .893 3.455 
Asian -.434 .669 .648 .088 4.758 
Native American .923 .372 2.516 .332 19.056 
Hispanic -.162 .714 .850 .357 2.025 
Marital Status 
Married  -.413 .185 .661 .359 1.219 
Divorced -.795 .194 .452 .136 1.499 
Legally Separated -.340 .739 .712 .096 5.281 
Widow .638 .409 1.894 .416 8.623 
Payer Type 
Medicaid -.218 .607 .804 .350 1.846 
Medicare -1.057 .074 .347 .109 1.110 
VA .944 .141 2.570 .732 9.020 
Uninsured .038 .899 1.039 .573 1.886 
Age 
25-34 .109 .782 1.116 .514 2.420 
35-44 .455 .245 1.577 .732 3.397 
45-64 -.020 .960 .980 .447 2.149 
65+ -1.280 .260 .278 .030 2.577 
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Multiple Drug Use 
Significant predictors of multiple drug use among all drug poisoning admissions 
were gender, payer source and age.  Among predictor characteristics, female gender was 
protective, where females had a 20% lower odds of having used multiple drugs.  
Medicaid, Medicare and uninsured cases had greater odds of multiple drug use (OR 1.66 
(p=.000 95% CI 1.41-1.97), 1.68 (p=.000, 95% CI 1.43 – 1.98) and 1.38 (p=.000, 95% CI 
1.20 – 1.57).  Persons 45-64 (OR=1.37 (p=.000, 95% CI 1.56-1.63) and 65 and older 
(OR=1.61 (p=.000, 95% CI 1.26 – 2.06) also had greater odds of polysubstance 
admissions.   
 
Table 12.  Predictors of Multiple Drug Use Among Drug Poisoning Admission Cases  
B Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Gender 
Female -.214 .000 .807 .732 .891 
Race 
Black .099 .217 1.104 .944 1.292 
Asian -.285 .086 .752 .544 1.041 
Native American .153 .606 1.166 .651 2.088 
Hispanic  -.012 .880 .988 .840 1.161 
Marital Status  
Married  .071 .237 1.073 .955 1.207 
Divorced -.077 .373 .926 .781 1.097 
Legally separated .061 .744 1.063 .737 1.532 
Widow .352 .009 1.421 1.094 1.847 
Payer Type 
Medicaid .509 .000 1.664 1.406 1.969 
Medicare .520 .000 1.681 1.426 1.982 
VA .069 .737 1.071 .718 1.599 
Uninsured  .319 .000 1.375 1.204 1.571 
Age 
25-34 .095 .301 1.099 .919 1.315 
35-44 .064 .495 1.066 .887 1.281 
45-64 .317 .000 1.374 1.155 1.633 
65+ 1 .000 1.614 1.264 2.062 
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Multiple Admissions (Repeat Cases) 
Female gender (p=.010, OR=.759 95% CI .615-.937), married marital status 
(p=.014, .718, 95% CI .551-.936) and black race (p=.002, OR=.525 95% CI .350-.787) 
race were all protective.  Females had 25% less odds of having multiple admissions when 
compared to males.  Married individuals had 30% lower odds of having multiple 
admissions when compared to single cases.  With regards to payer status, admissions that 
had a payer source of Medicaid and Medicare had greater odds of having a multiple 
admission (OR=1.48 (p=.030 95 CI 1.04 – 2.10) and 1.68 (p=.003 95% CI 1.12 – 2.36) 
respectively). 
 
Table 13.  Predictors of Multiple Unintentional Prescription Drug Poisoning Admissions 
by Select Characteristics  
B 
Sig. Exp(B) 95% C.I.for EXP(B) 
    Lower Upper 
Gender 
Female -.275 .010 .759 .615 .937 
Race 
Black -.644 .002 .525 .350 .787 
Asian -18.301 .995 .000 0.000   
Native American -1.165 .251 .312 .043 2.280 
Hispanic -.243 .190 .784 .545 1.128 
Marital Status 
Married -.331 .014 .718 .551 .936 
Divorced -.017 .920 .983 .705 1.371 
Legally Separated .037 .921 1.038 .497 2.169 
Widow -.218 .470 .804 .445 1.453 
Payer Source 
Medicaid .390 .030 1.477 1.040 2.099 
Medicare .518 .003 1.678 1.196 2.355 
VA Champus -1.094 .131 .335 .081 1.385 
Self Pay .027 .859 1.027 .764 1.381 
Age 
25-34 .033 .871 1.033 .695 1.537 
35-44 -.030 .884 .970 .645 1.458 
45-64 .302 .112 1.353 .932 1.964 
65+ -.432 .132 .649 .370 1.139 
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CHAPTER 6 
DISCUSSION, CONCLUSION AND RECOMMENDATIONS 
 
This study aimed to examine the occurrence and distribution of prescription drug 
poisoning admissions to emergency departments and inpatient units at hospitals in Clark 
County, Nevada between 2009-2013 in order to describe the demographic characteristics 
and their relationship to specified outcomes.   Demographic characteristics were selected 
based on review of related literature.   
Females were overrepresented in the drug poisoning (DP) counts, percentages and 
rates in every year included in this analysis.  This conflicts with some of the reports using 
national statistics which suggest that although females have experienced sharper 
increases in DP in recent years, overall, males experience higher rates of drug poisonings.  
However, other studies have demonstrated a differential risk for women.  Cohen et al., 
found that in comparison to patients hospitalized for poisoning from other substances, 
those hospitalized for prescription opioids, sedatives, and tranquilizers were more likely 
to be women, aged >34 years, and to present to a rural or urban nonteaching hospital 
(Cohen, 2010).  The prominent involvement of benzodiazepines in female DPs may 
contribute to the differential risk for women.  Among our study population, women were 
38% more likely to have a DP attributed to a benzodiazepine when compared to males.  
This finding provides insight for targeted prevention opportunities.   
Information from this study is consistent with the national pattern of DP among 
different age groups.  Persons aged 35-64 were more frequently represented in our 
population.   This trend may be related to the prevalence of chronic long-term opioid 
users.  Currently, more than 3% of US adults receive long-term opioid therapy for 
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chronic non-cancer pain and patients that are on long-term regimens tend to take higher 
doses which puts them at greater risk (Okie, 2010).   This may also contribute to the 
higher incidence among persons 65 and older, a group with more complex medical 
conditions that may be treated with narcotic pain medication.   
In addition, the study showed an increase in the rate among persons 65 and older.  
It is important to note is that persons in this age group were more frequently admitted to 
the hospital whereas the other age groups are more frequently seen in the ED only. This 
is likely because older populations have more complex underlying medical conditions 
which may complicate the clinical course of a drug poisoning event. Additionally, they 
were 1.6 times more likely to have multiple drugs in their system upon admission, which 
may have resulted in a greater hospital admission rate.   
With regards to race, Native Americans exhibited the most dramatic increase in 
DP rates.  CDC also reported that age-adjusted death rates in 2010 were highest among 
this same group (NCHS, 2012).  Although numbers of DP admissions are relatively low 
among Native Americans, these findings suggest a potentially emerging problem in this 
population that warrants further study.   
Although the percentage of DP involving alcohol was small, we were able to 
determine that males had greater odds of a combined drug and alcohol overdose when 
compared to females.  This finding is consistent with patterns of drinking and alcohol 
abuse described in the literature that indicate males have higher rates of alcohol 
consumption (White, 2011).   The role of combined alcohol and drug overdose may be 
grossly underestimated in this study due to the methods we used for inclusion to construct 
our study population.  Cases were included only if their primary diagnosis indicated 
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poisoning by one of the selected drug categories. Admissions that listed alcohol 
poisoning as a primary diagnosis were excluded even if they had an E-code indicating 
combined alcohol and drug use.  Including admissions coded as alcohol poisoning also 
involving a prescription drug as indicated by the listed E-codes may yield a different and 
important result and should be considered for future studies.   
Males also had higher odds of a poisoning involving multiple drugs and having a 
repeat visit within a year for a DP.  These findings suggest that although females have 
higher rates of DP admissions overall, males may engage in more dangerous drug use 
behaviors that puts them at risk for multiple hospitalizations and possibly death.  The 
warning label on some Percoset containers, an opioid medication containing oxycodone, 
states, “Oxycodone may be expected to have additive effects when used in conjunction 
with alcohol, other opioids or illicit drugs that cause central nervous system depression” 
(White, 2011).   
Some studies have suggested an emerging problem of drug poisonings associated 
with methadone, an opioid traditionally used in the treatment of heroin abuse.  A study 
conducted by the CDC of prescription overdose deaths in Washington from 2004-2007 of 
identified Medicaid enrollees, demonstrated increased risk and the relationship between 
methadone and overdose in this population (MMWR, 2009).   Our findings did not 
support this.  Methadone poisonings represented only 3.4% of DPs in the Medicaid 
population and 3% of the overall admissions in all categories.  However, because the 
national data suggest that methadone is being increasingly used in the treatment of 
chronic pain, likely because it is relatively cheap, it has been observed to play a 
prominent role in overdose mortality.  Further observation of the trend is recommended.   
 45 
 
Although, beyond of the scope of this study, the increase in drug poisonings is 
thought to be a consequence of nonmedical use of opioids and other prescription drugs.  
Our study showed that a large percentage of drug poisonings occurred among uninsured 
persons.  Uninsured was defined as self, discounted, negotiated rate and indigent payer 
sources.  This may indicate that this population is acquiring prescription drugs through 
nonmedical distribution channels or namely, diversion.  Studies have shown that most 
(60%) persons who use prescription drugs non-medically obtain them from a friend or 
family member to whom they were prescribed (CDC, 2010).   One in every five 
Americans is prescribed a prescription pain medication each day (CCOME, 2012) and 
enough medication is prescribed to dose every adult American for one month.  The 
increase in prescriptions and sales has led to an increase in accessibility.  Our study 
supports diversion as a probable factor in the DP epidemic in Clark County.   
The findings of this study provide information to suggest that interventions should 
be targeted at several demographic groups.  Non-Hispanic whites, men and women aged 
35-64 and poorer populations (we used Medicaid and uninsured payer source as a proxy) 
would benefit from risk reduction programs including education, substance abuse 
treatment and monitoring.  In addition, Native Americans and persons over 65, groups 
that show a more recent upward trend in DP admissions, should also be targeted to reduce 
prescription drug poisonings.   
Limitations 
There are several limitations inherent to this study.  It is possible that some of our 
findings were an artifact of a small sample size or collinear effects.  For example, the rate 
increase observed among Native Americans may be due to the relatively small population 
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size.  The regression model may have been affected by multicollinearity where 
independent variables like single marital status and public medical insurance may have 
been highly correlated, as they are both potentially indicators of lower socio-economic 
status.  As such, it may be low SES that is the true predictor of multiple admissions rather 
than the individual independent variables.     
The case selection methodology may have resulted in an underestimate of alcohol 
involvement in unintentional prescription drug poisoning admissions. Cases were 
included if they had a primary diagnosis indicating poisoning by methadone, opiates, 
antidepressants or benzodiazepines.  Admissions where alcohol poisoning was listed as 
the primary diagnosis were excluded even if the admission listed a corresponding E-code.  
Additionally, the case selection method was dependent on the accurate coding by medical 
personnel at the reporting hospitals.  It is possible that cases were missed due to provider 
bias in diagnosing and/or coding diagnoses.  It is also possible that E-codes were missing 
from records and as such were excluded from our analysis.  Data quality is dependent on 
coding by specific hospitals, which may differ by hospital or coder.   
Another limitation associated with coding of drug poisonings is that the codes are 
not specific enough to determine which specific drug was contributory in each category.  
Future studies should examine the possibilities of selecting for codes that indicate the 
specific drug type involved in the poisoning, ie. Oxycodone.   
With regards to selecting for repeat cases we were limited by the strength of the 
probabilistic method employed by CHIA to track persons over time, namely, repeat cases 
could only be identified within a calendar year and within a data set (inpatient or ED). 
We were not able to assess for how poisoning deaths may have impacted the accuracy of 
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our analysis of repeat cases because data linkages cannot be made between data sets. This 
may have particularly impacted our analysis of repeat admissions as persons who die do 
not have the opportunity to be admitted multiple times.  Future studies should include 
disposition at discharge to help control for fatal outcomes. 
Conclusions and Recommendations  
 Changes in the medical use of opioid analgesics and related drugs led to a 
flooding in the U.S. of pharmaceuticals with high potential for dependency and abuse.  
The incidence of prescription drug poisoning has risen dramatically and is a significant 
factor making poisoning the leading cause of injury related mortality in the U.S.  
Prescription drug poisoning mortality is most strongly associated with opioid analgesics 
and related drugs often co-prescribed such as benzodiazepines and antidepressants.  In 
Clark County, Nevada, the rate of fatal poisonings involving opioid pain analgesics is 
above the national rate.  Many of these deaths involve sedatives and tranquilizers.  This 
study demonstrated that these same drugs are important contributors to the morbidity 
associated with prescription drugs, particularly among women.   
Unintentional injuries are preventable. In Clark County, Nevada, public health 
interventions that target non-Hispanic white men and women age 35-64, Native 
Americans and persons 65 may help prevent prescription drug poisonings from occurring.  
Studies like this should be replicated and expounded upon to further define the risk 
population and gain an understanding of the risk factors in order to develop strategies to 
reduce risk and the associated morbidity and mortality burden.   
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